Vazkepa recommended for approval in New Zealand | AMRN Message Board Posts


Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  9067 of 9093  at  7/6/2022 7:53:55 PM  by

lettruthringout


Vazkepa recommended for approval in New Zealand

 

Vazkepa is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and

  • established cardiovascular disease, or
  • diabetes, and at least one other cardiovascular risk factor.
Recommendation

That icosapent ethyl should be added to the New Zealand schedule as a prescription medicine.

https://www.medsafe.govt.nz/profs/class/Minutes/2021-2025/mccMin26Apr2022.htm



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 6  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...